Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings.1 ...

While these won’t cure hep C, lifestyle and diet changes can support your health while you receive treatment — and beyond. Remember to discuss any changes to your health routine with your care ...

NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

About 1,200 Germans are diagnosed with gastrointestinal stromal tumors every year—a rare type of cancer in which the tumors ...

By Dr. Joseph Kim University of Kentucky Liver cancer is the sixth leading cause cancer death in the U.S. The most common ...

The following is a summary of "Feasibility and Performance of a Point-of-Care Hepatitis C RNA Assay in a Community ...

Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ALGS, “Aligos”), a clinical ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Liver cancer is the sixth leading cause cancer death in the U.S. The most common type of liver cancer in adults is ...

Regular Abstracts Accepted as Poster Presentations Presentation Title: Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated ...

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial ...